Venifixe: phytovanoactive topical infused oil for healing and preventing epidermal and venous ailments

Background: This study investigates Venifixe®, a cost-effective phyto-vanoactive infused oil, as an alternative treatment for epidermal and venous ailments (EVA). Venifixe® combines venoactive phyto-complexes, hydrophilic botanical extracts, essential oils, carrier oils, and epidermal care components. The study strives to offer a non-invasive and potentially more effective alternative to conventional treatments, aiming to improve or prevent various EVAs and enhance patients' quality of life. Despite the array of existing treatments, there remains a need for formulations offering enhanced efficacy, reduced invasiveness, and broader applicability. Methods: Over twelve weeks, 250 participants (average age: 59.91±7.25 years), diagnosed with varicosities via ultrasonography, were included. Participants were divided into two groups: 142 received standard management (SM) for symptomatic EVA, and 108 received Venifixe® treatment. Both groups were assessed for EVA-related symptoms (pain, itchiness, restlessness, swelling/edema, heaviness, and leg cramps) and Venous Clinical Severity Score (VCSS) based on CEAP classification pre-and post-treatment. Results: At twelve weeks, the Venifixe® group demonstrated a VCSS ROC curve (AUC=0.905, 95% CI: 0.89-0.92, p<0.0001), with 93.68% sensitivity, 61.11% specificity, and 75.43% accuracy, indicating favorable treatment outcomes. Significant reductions in VCSS risk ratios and associated symptom prevalence (p<0.0001) led to an improved NHS gradation scale from level 3 to level 2 compared to the SM group. Conclusions: Venifixe®'s topical application provides a more effective phytotherapeutic approach for EVA compared to standard management, offering symptom relief and enhancing quality of life. These results, supported by ROC curves and NHS gradation improvements, warrant further clinical investigation.